Buscar
Celcuity Inc
CELCAñadir a la lista de seguimiento
86.380USD
-1.260-1.44%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
4.18BCap. mercado
PérdidaP/E TTM
Más Datos de Celcuity Inc Compañía
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Información de Celcuity Inc
Símbolo de cotizaciónCELC
Nombre de la empresaCelcuity Inc
Fecha de salida a bolsaSep 20, 2017
Director ejecutivoSullivan (Brian F)
Número de empleados87
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 20
Dirección16305 36th Ave N Ste 100
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal55446-4285
Teléfono17633920767
Sitio Webhttps://www.celcuity.com/
Símbolo de cotizaciónCELC
Fecha de salida a bolsaSep 20, 2017
Director ejecutivoSullivan (Brian F)
Ejecutivos de Celcuity Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
--
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
80.56K
+1.90%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
19.81K
+4.79%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
8.29K
+18.46%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
6.53K
+23.43%
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
--
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
80.56K
+1.90%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
19.81K
+4.79%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
8.29K
+18.46%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
6.53K
+23.43%
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Celcuity Inc?
Los cinco principales accionistas de Celcuity Inc son: Mr. Brian F. Sullivan
¿Cuántas instituciones poseen acciones de Celcuity Inc (CELC)?
A fecha de 2026Q1, 415 instituciones poseen acciones de Celcuity Inc, con un valor de mercado combinado de aproximadamente 47.21M, lo que representa el 97.67% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1586164.00.